Aashish Manglik, MD, PhD, and Team Create Antiviral Nanobody Effective Against SARS-CoV-2 in the Lab

Aashish Manglik, MD, PhD, in the lab

See the full story on UCSF.edu, or the article pre-print, here.

Aerosolizer in the Manglik LabAn ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation. Michael Schoof, Bryan Faust, Reuben A. Saunders, Smriti Sangwan, Veronica Rezelj, Nick Hoppe, Morgane Boone, Christian Bache Billesbølle, Marcell Zimanyi, Ishan Deshpande, Jiahao Liang, Aditya A. Anand, Niv Dobzinski, Beth Shoshana Zha, Benjamin Barsi-Rhyne, Vladislav Belyy, Andrew W. Barile-Hill, Sayan Gupta, Camille R. Simoneau, Kristoffer Leon, Kris M. White, Silke Nock, Yuwei Liu, Nevan J. Krogan, Corie Y. Ralston, Danielle L. Swaney, Adolfo García-Sastre, Melanie Ott, Marco Vignuzzi, QCRG Structural Biology Consortium, Peter Walter,  Aashish Manglik.

Research team in the labAashish Manglik (left), MD, PhD, and Peter Walter, PhD; Researcher in the labAerosolizer in the Manglik Lab